Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Find generic entry opportunities
Proactively manage your pharmacy inventory
Drug patents …
… from Kazakhstan to Kalamazoo
Manage your formulary budget
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Abstract:||A hydromorphone composition, a hydromorphone dosage form and a method for administering hydromorphone are disclosed, indicated for the management of pain.|
|Inventor(s):||Merrill; Sonya (San Jose, CA), Ayer; Atul D. (Palo Alto, CA), Chadha; Navjot (Sunnyvale, CA), Kuczynski; Anthony L. (Mt. View, CA)|
|Assignee:||Alza Corporation (Palo Alto, CA)|
|Filing Date:||Jul 07, 1994|
|Claims:||1. A therapeutic composition for the relief of pain comprising 1 to 1000 mg of hydromorphone, 25 to 500 mg of a carboxymethylcellulose possessing a 10,000 to 300,000 molecular weight, 1 to 50 mg of a poly(vinylpyrrolidone) having a 10,000 to 300,000 molecular weight and 0 to 7.5 mg of a lubricant, which therapeutic composition is encased with a semipermeable wall with a passageway through the semipermeable composition. |
2. A bilayer comprising a hydromorphone composition that comprises 1 to 1000 mg of hydromorphone. 25 to 500 mg of a carboxymethylcellulose possessing a 10,000 to 300,000 molecular weight, 1 to 50 mg of a poly (vinylpyrrolidone) having, a 10,000 to 300,000 molecular weight, and 0 to 7.5 mg of a lubricant; and an push composition comprising 15 to 250 mg of a poly(alkylene oxide) of 3,000,000 to 7,500,000 molecular weight, 0 to 75 mg of an osmagent, 1 to 50 mg of a hydroxyalkylcellulose, 0 to 10 mg of a tableting lubricant, 0 to 10 mg of an antioxidant, and 0 to 10 mg of a colorant.
3. A method for administering hydromorphone, to a patient in need of pain relief which method comprises admitting orally into the patient a composition comprising 1 to 1000 mg of hydromorphone, 25 to 500 mg of a poly(alkylene oxide) possessing a 150,000 to 500,000 molecular weight, 1 to 50 mg of poly(vinyl pyrrolidone) possessing a 10,000 to 300,000 molecular weight, and 0 to 7.5 mg of a lubricant, an push composition comprising a carboxymethylcellulose having a 450,000 to 2,500,000 molecular weight, and wherein the method administers the hydromorphone at a sustained rate over time for the relief of pain.
4. The method for administering the hydromorphone according to claim 3, wherein the hydromorphone composition and the push composition are surrounded by a semipermeable wall permeable to aqueous biological fluid. and impermeable to the passage of hydromorphone, with a passageway in the semipermeable wall, the poly(alkylene) is replaced by carboxymethylcellulose possessing a 10,000 to 300,000 molecular weight for administering the hydromorphone to the patient for the relief of pain.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.